首页> 外文期刊>Oncology Research >Alterations found in pl6/Rb/cyclin D1 pathway in the dysplastic and malignant cervical epithelium.
【24h】

Alterations found in pl6/Rb/cyclin D1 pathway in the dysplastic and malignant cervical epithelium.

机译:在增生性和恶性宫颈上皮中的pl6 / Rb / cyclin D1途径中发现了改变。

获取原文
获取原文并翻译 | 示例
       

摘要

Cervical cancer is the one of the most common cancers affecting the south Indian women. The objective of the present study was to analyze the pl6/Rb/cyclin D1 pathway in the normal (n=30), dysplastic (n=56), and malignant cervical epithelium (n=142) using immunohistochemistry. The positive immunoreactivity for p16 was as follows: CIN I--1/12 (8.3%), CIN II--2/8 (25%), CIN III--31/36 (86.1%), and in invasive tumors-121/142 (85.1%); for cyclin D1 it was CIN I--4/12 (66.6%), CIN II--5/8 (62.5%), CIN III--0%, and invasive tumors--5/142 (3.5%); and for pRb it was CIN I--9/12 (75%), CIN II--5/8(62.5%), CIN III--1/36 (97.2%), and in invasive tumors--41/142 (28.8%). Expression of cyclin D1 and p16 in the CINs were mutually exclusive and the correlation between the two biomarkers was found to be statistically significant (p = 0.0009). There was downregulation of pRb in invasive cancers, with only 32% (39/121) of the p16-positive tumors being positive for pRb (p = 0.032). Analysis of the pattern of expression ofthese biomolecules showed increased p16-positive phenotypes and decreased cyclin D1- and pRB-positive phenotype among the invasive tumors compared to low-grade CIN lesions.
机译:宫颈癌是影响南印度妇女的最常见癌症之一。本研究的目的是使用免疫组织化学分析正常(n = 30),发育不良(n = 56)和恶性宫颈上皮(n = 142)中的pl6 / Rb / cyclin D1途径。 p16的阳性免疫反应性如下:CIN I--1 / 12(8.3%),CIN II--2 / 8(25%),CIN III--31 / 36(86.1%),以及在浸润性肿瘤中121/142(85.1%);对于细胞周期蛋白D1,它是CIN I--4 / 12(66.6%),CIN II--5 / 8(62.5%),CIN III--0%和浸润性肿瘤--5 / 142(3.5%);对于pRb,在CIN I--9 / 12(75%),CIN II--5 / 8(62.5%),CIN III--1 / 36(97.2%)和浸润性肿瘤中为41/142 (28.8%)。 CIN中细胞周期蛋白D1和p16的表达是互斥的,并且发现两个生物标记之间的相关性具有统计学意义(p = 0.0009)。浸润性癌症中pRb的表达下调,只有32%(39/121)的p16阳性肿瘤中pRb呈阳性(p = 0.032)。与低度CIN病变相比,侵袭性肿瘤中这些生物分子表达模式的分析显示p16阳性表型增加,而cyclin D1和pRB阳性表型减少。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号